Search This Blog

Sunday, May 15, 2022

Classification of mental disorders

From Wikipedia, the free encyclopedia

The classification of mental disorders is also known as psychiatric nosology or psychiatric taxonomy. It represents a key aspect of psychiatry and other mental health professions and is an important issue for people who may be diagnosed. There are currently two widely established systems for classifying mental disorders:

Both list categories of disorders thought to be distinct types, and have deliberately converged their codes in recent revisions so that the manuals are often broadly comparable, although significant differences remain. Other classification schemes may be in use more locally, for example the Chinese Classification of Mental Disorders. Other manuals have some limited use by those of alternative theoretical persuasions, such as the Psychodynamic Diagnostic Manual.

The widely used DSM and ICD classifications employ operational definitions.

Definitions

In the scientific and academic literature on the definition or categorization of mental disorders, one extreme argues that it is entirely a matter of value judgments (including of what is normal) while another proposes that it is or could be entirely objective and scientific (including by reference to statistical norms); other views argue that the concept refers to a "fuzzy prototype" that can never be precisely defined, or that the definition will always involve a mixture of scientific facts (e.g. that a natural or evolved function isn't working properly) and value judgments (e.g. that it is harmful or undesired). Lay concepts of mental disorder vary considerably across different cultures and countries, and may refer to different sorts of individual and social problems.

The WHO and national surveys report that there is no single consensus on the definition of mental disorder, and that the phrasing used depends on the social, cultural, economic and legal context in different contexts and in different societies. The WHO reports that there is intense debate about which conditions should be included under the concept of mental disorder; a broad definition can cover mental illness, intellectual disability, personality disorder and substance dependence, but inclusion varies by country and is reported to be a complex and debated issue. There may be a criterion that a condition should not be expected to occur as part of a person's usual culture or religion. However, despite the term "mental", there is not necessarily a clear distinction drawn between mental (dys)functioning and brain (dys)functioning, or indeed between the brain and the rest of the body.

Most international clinical documents avoid the term "mental illness", preferring the term "mental disorder". However, some use "mental illness" as the main overarching term to encompass mental disorders. Some consumer/survivor movement organizations oppose use of the term "mental illness" on the grounds that it supports the dominance of a medical model. The term "serious mental impairment" (SMI) is sometimes used to refer to more severe and long-lasting disorders while "mental health problems" may be used as a broader term, or to refer only to milder or more transient issues. Confusion often surrounds the ways and contexts in which these terms are used.

Mental disorders are generally classified separately to neurological disorders, learning disabilities or mental retardation.

ICD-10

The International Classification of Diseases (ICD) is an international standard diagnostic classification for a wide variety of health conditions. The ICD-10 states that mental disorder is "not an exact term", although is generally used "...to imply the existence of a clinically recognisable set of symptoms or behaviours associated in most cases with distress and with interference with personal functions." Chapter V focuses on "mental and behavioural disorders" and consists of 10 main groups:

  • F0: Organic, including symptomatic, mental disorders
  • F1: Mental and behavioural disorders due to use of psychoactive substances
  • F2: Schizophrenia, schizotypal and delusional disorders
  • F3: Mood [affective] disorders
  • F4: Neurotic, stress-related and somatoform disorders
  • F5: Behavioural syndromes associated with physiological disturbances and physical factors
  • F6: Disorders of personality and behaviour in adult persons
  • F7: Mental retardation
  • F8: Disorders of psychological development
  • F9: Behavioural and emotional disorders with onset usually occurring in childhood and adolescence
  • In addition, a group of "unspecified mental disorders".

Within each group there are more specific subcategories. The WHO has revised ICD-10 to produce the latest version of the ICD, ICD-11 adopted by the 72nd World Health Assembly in 2019 and came into effect on 1 January 2022.

DSM-IV

The DSM-IV was originally published in 1994 and listed more than 250 mental disorders. It was produced by the American Psychiatric Association and it characterizes mental disorder as "a clinically significant behavioral or psychological syndrome or pattern that occurs in an individual,...is associated with present distress...or disability...or with a significantly increased risk of suffering" but that "...no definition adequately specifies precise boundaries for the concept of 'mental disorder'...different situations call for different definitions" (APA, 1994 and 2000). The DSM also states that "there is no assumption that each category of mental disorder is a completely discrete entity with absolute boundaries dividing it from other mental disorders or no mental disorders."

The DSM-IV-TR (Text Revision, 2000) consisted of five axes (domains) on which disorder could be assessed. The five axes were:

Axis I: Clinical Disorders (all mental disorders except Personality Disorders and Mental Retardation)
Axis II: Personality Disorders and Mental Retardation
Axis III: General Medical Conditions (must be connected to a Mental Disorder)
Axis IV: Psychosocial and Environmental Problems (for example limited social support network)
Axis V: Global Assessment of Functioning (Psychological, social and job-related functions are evaluated on a continuum between mental health and extreme mental disorder)

The axis classification system was removed in the DSM-5 and is now mostly of historical significance. The main categories of disorder in the DSM are:

DSM Group Examples
Disorders usually first diagnosed in infancy, childhood or adolescence. *Disorders such as ADHD and epilepsy have also been referred to as developmental disorders and developmental disabilities. ADHD
Delirium, dementia, and amnesia and other cognitive disorders Alzheimer's disease
Mental disorders due to a general medical condition AIDS-related psychosis
Substance-related disorders Alcohol use disorder
Schizophrenia and other psychotic disorders Delusional disorder
Mood disorders Major depressive disorder, Bipolar disorder
Anxiety disorders Generalized anxiety disorder, Social anxiety disorder
Somatoform disorders Somatization disorder
Factitious disorders Münchausen syndrome
Dissociative disorders Dissociative identity disorder
Sexual and gender dysphoria Dyspareunia, Gender dysphoria
Eating disorders Anorexia nervosa, Bulimia nervosa
Sleep disorders Insomnia
Impulse control disorders not elsewhere classified Kleptomania
Adjustment disorders Adjustment disorder
Personality disorders Narcissistic personality disorder
Other conditions that may be a focus of clinical attention Tardive dyskinesia, Child abuse

Other schemes

Childhood diagnosis

Child and adolescent psychiatry sometimes uses specific manuals in addition to the DSM and ICD. The Diagnostic Classification of Mental Health and Developmental Disorders of Infancy and Early Childhood (DC:0-3) was first published in 1994 by Zero to Three to classify mental health and developmental disorders in the first four years of life. It has been published in 9 languages. The Research Diagnostic criteria-Preschool Age (RDC-PA) was developed between 2000 and 2002 by a task force of independent investigators with the goal of developing clearly specified diagnostic criteria to facilitate research on psychopathology in this age group. The French Classification of Child and Adolescent Mental Disorders (CFTMEA), operational since 1983, is the classification of reference for French child psychiatrists.

Usage

The ICD and DSM classification schemes have achieved widespread acceptance in psychiatry. A survey of 205 psychiatrists, from 66 countries across all continents, found that ICD-10 was more frequently used and more valued in clinical practice and training, while the DSM-IV was more frequently used in clinical practice in the United States and Canada, and was more valued for research, with accessibility to either being limited, and usage by other mental health professionals, policy makers, patients and families less clear. . A primary care (e.g. general or family physician) version of the mental disorder section of ICD-10 has been developed (ICD-10-PHC) which has also been used quite extensively internationally. A survey of journal articles indexed in various biomedical databases between 1980 and 2005 indicated that 15,743 referred to the DSM and 3,106 to the ICD.

In Japan, most university hospitals use either the ICD or DSM. ICD appears to be the somewhat more used for research or academic purposes, while both were used equally for clinical purposes. Other traditional psychiatric schemes may also be used.

Types of classification schemes

Categorical schemes

The classification schemes in common usage are based on separate (but may be overlapping) categories of disorder schemes sometimes termed "neo-Kraepelinian" (after the psychiatrist Kraepelin) which is intended to be atheoretical with regard to etiology (causation). These classification schemes have achieved some widespread acceptance in psychiatry and other fields, and have generally been found to have improved inter-rater reliability, although routine clinical usage is less clear. Questions of validity and utility have been raised, both scientifically and in terms of social, economic and political factors—notably over the inclusion of certain controversial categories, the influence of the pharmaceutical industry, or the stigmatizing effect of being categorized or labelled.

Non-categorical schemes

Some approaches to classification do not use categories with single cut-offs separating the ill from the healthy or the abnormal from the normal (a practice sometimes termed "threshold psychiatry" or "dichotomous classification").

Classification may instead be based on broader underlying "spectra", where each spectrum links together a range of related categorical diagnoses and nonthreshold symptom patterns.

Some approaches go further and propose continuously varying dimensions that are not grouped into spectra or categories; each individual simply has a profile of scores across different dimensions. DSM-5 planning committees are currently seeking to establish a research basis for a hybrid dimensional classification of personality disorders. However, the problem with entirely dimensional classifications is they are said to be of limited practical value in clinical practice where yes/no decisions often need to be made, for example whether a person requires treatment, and moreover the rest of medicine is firmly committed to categories, which are assumed to reflect discrete disease entities. While the Psychodynamic Diagnostic Manual has an emphasis on dimensionality and the context of mental problems, it has been structured largely as an adjunct to the categories of the DSM. Moreover, dimensionality approach was criticized for its reliance on independent dimensions whereas all systems of behavioral regulations show strong inter-dependence, feedback and contingent relationships. 

Descriptive vs Somatic

Descriptive classifications are based almost exclusively on either descriptions of behavior as reported by various observers, such as parents, teachers, and medical personnel; or symptoms as reported by individuals themselves. As such, they are quite subjective, not amenable to verification by third parties, and not readily transferable across chronologic and/or cultural barriers.

Somatic nosology, on the other hand, is based almost exclusively on the objective histologic and chemical abnormalities which are characteristic of various diseases and can be identified by appropriately trained pathologists. While not all pathologists will agree in all cases, the degree of uniformity allowed is orders of magnitude greater than that enabled by the constantly changing classification embraced by the DSM system. Some models, like Functional Ensemble of Temperament suggest to unify nosology of somatic, biologically based individual differences in healthy people (temperament) and their deviations in a form of mental disorders in one taxonomy.

Cultural differences

Classification schemes may not apply to all cultures. The DSM is based on predominantly American research studies and has been said to have a decidedly American outlook, meaning that differing disorders or concepts of illness from other cultures (including personalistic rather than naturalistic explanations) may be neglected or misrepresented, while Western cultural phenomena may be taken as universal. Culture-bound syndromes are those hypothesized to be specific to certain cultures (typically taken to mean non-Western or non-mainstream cultures); while some are listed in an appendix of the DSM-IV they are not detailed and there remain open questions about the relationship between Western and non-Western diagnostic categories and sociocultural factors, which are addressed from different directions by, for example, cross-cultural psychiatry or anthropology.

Historical development

Antiquity

In Ancient Greece, Hippocrates and his followers are generally credited with the first classification system for mental illnesses, including mania, melancholia, paranoia, phobias and Scythian disease (transvestism). They held that they were due to different kinds of imbalance in four humors.

Middle ages to Renaissance

The Persian physicians 'Ali ibn al-'Abbas al-Majusi and Najib ad-Din Samarqandi elaborated upon Hippocrates' system of classification. Avicenna (980−1037 CE) in the Canon of Medicine listed a number of mental disorders, including "passive male homosexuality".

Laws generally distinguished between "idiots" and "lunatics".

Thomas Sydenham (1624–1689), the "English Hippocrates", emphasized careful clinical observation and diagnosis and developed the concept of a syndrome, a group of associated symptoms having a common course, which would later influence psychiatric classification.

18th century

Evolution in the scientific concepts of psychopathology (literally referring to diseases of the mind) took hold in the late 18th and 19th centuries following the Renaissance and Enlightenment. Individual behaviors that had long been recognized came to be grouped into syndromes.

Boissier de Sauvages developed an extremely extensive psychiatric classification in the mid-18th century, influenced by the medical nosology of Thomas Sydenham and the biological taxonomy of Carl Linnaeus. It was only part of his classification of 2400 medical diseases. These were divided into 10 "classes", one of which comprised the bulk of the mental diseases, divided into four "orders" and 23 "genera". One genus, melancholia, was subdivided into 14 "species".

William Cullen advanced an influential medical nosology which included four classes of neuroses: coma, adynamias, spasms, and vesanias. The vesanias included amentia, melancholia, mania, and oneirodynia.

Towards the end of the 18th century and into the 19th, Pinel, influenced by Cullen's scheme, developed his own, again employing the terminology of genera and species. His simplified revision of this reduced all mental illnesses to four basic types. He argued that mental disorders are not separate entities but stem from a single disease that he called "mental alienation".

Attempts were made to merge the ancient concept of delirium with that of insanity, the latter sometimes described as delirium without fever.

On the other hand, Pinel had started a trend for diagnosing forms of insanity 'without delirium' (meaning hallucinations or delusions) – a concept of partial insanity. Attempts were made to distinguish this from total insanity by criteria such as intensity, content or generalization of delusions.

19th century

Pinel's successor, Esquirol, extended Pinel's categories to five. Both made a clear distinction between insanity (including mania and dementia) as opposed to mental retardation (including idiocy and imbecility). Esquirol developed a concept of monomania—a periodic delusional fixation or undesirable disposition on one theme—that became a broad and common diagnosis and a part of popular culture for much of the 19th century. The diagnosis of "moral insanity" coined by James Prichard also became popular; those with the condition did not seem delusional or intellectually impaired but seemed to have disordered emotions or behavior.

The botanical taxonomic approach was abandoned in the 19th century, in favor of an anatomical-clinical approach that became increasingly descriptive. There was a focus on identifying the particular psychological faculty involved in particular forms of insanity, including through phrenology, although some argued for a more central "unitary" cause. French and German psychiatric nosology was in the ascendency. The term "psychiatry" ("Psychiatrie") was coined by German physician Johann Christian Reil in 1808, from the Greek "ψυχή" (psychē: "soul or mind") and "ιατρός" (iatros: "healer or doctor"). The term "alienation" took on a psychiatric meaning in France, later adopted into medical English. The terms psychosis and neurosis came into use, the former viewed psychologically and the latter neurologically.

In the second half of the century, Karl Kahlbaum and Ewald Hecker developed a descriptive categorizion of syndromes, employing terms such as dysthymia, cyclothymia, catatonia, paranoia and hebephrenia. Wilhelm Griesinger (1817–1869) advanced a unitary scheme based on a concept of brain pathology. French psychiatrists Jules Baillarger described "folie à double forme" and Jean-Pierre Falret described "la folie circulaire"—alternating mania and depression.

The concept of adolescent insanity or developmental insanity was advanced by Scottish Asylum Superintendent and Lecturer in Mental Diseases Thomas Clouston in 1873, describing a psychotic condition which generally impacts those aged 18–24 years, particularly males, and in 30% of cases proceeded to "a secondary dementia".

The concept of hysteria (wandering womb) had long been used, perhaps since ancient Egyptian times, and was later adopted by Freud. Descriptions of a specific syndrome now known as somatization disorder were first developed by the French physician, Paul Briquet in 1859.

An American physician, Beard, described "neurasthenia" in 1869. German neurologist Westphal, coined the term "obsessional neurosis" now termed obsessive-compulsive disorder, and agoraphobia. Alienists created a whole new series of diagnoses that highlighted single, impulsive behavior, such as kleptomania, dipsomania, pyromania, and nymphomania. The diagnosis of drapetomania was also developed in the Southern United States to explain the perceived irrationality of black slaves trying to escape what was thought to be a suitable role.

The scientific study of homosexuality began in the 19th century, informally viewed either as natural or as a disorder. Kraepelin included it as a disorder in his Compendium der Psychiatrie that he published in successive editions from 1883.

"Psychiatrists of Europe! Protect your sanctified diagnoses!" Cartoon by Emil Kraepelin, 1896.

In the late 19th century, Koch referred to "psychopathic inferiority" as a new term for moral insanity. In the 20th century the term became known as "psychopathy" or "sociopathy", related specifically to antisocial behavior. Related studies led to the DSM-III category of antisocial personality disorder.

20th century

Influenced by the approach of Kahlbaum and others, and developing his concepts in publications spanning the turn of the century, German psychiatrist Emil Kraepelin advanced a new system. He grouped together a number of existing diagnoses that appeared to all have a deteriorating course over time—such as catatonia, hebephrenia and dementia paranoides—under another existing term "dementia praecox" (meaning "early senility", later renamed schizophrenia). Another set of diagnoses that appeared to have a periodic course and better outcome were grouped together under the category of manic-depressive insanity (mood disorder). He also proposed a third category of psychosis, called paranoia, involving delusions but not the more general deficits and poor course attributed to dementia praecox. In all he proposed 15 categories, also including psychogenic neurosis, psychopathic personality, and syndromes of defective mental development (mental retardation). He eventually included homosexuality in the category of "mental conditions of constitutional origin".

The neuroses were later split into anxiety disorders and other disorders.

Freud wrote extensively on hysteria and also coined the term, "anxiety neurosis", which appeared in DSM-I and DSM-II. Checklist criteria for this led to studies that were to define panic disorder for DSM-III.

Early 20th century schemes in Europe and the United States reflected a brain disease (or degeneration) model that had emerged during the 19th century, as well as some ideas from Darwin's theory of evolution and/or Freud's psychoanalytic theories.

Psychoanalytic theory did not rest on classification of distinct disorders, but pursued analyses of unconscious conflicts and their manifestations within an individual's life. It dealt with neurosis, psychosis, and perversion. The concept of borderline personality disorder and other personality disorder diagnoses were later formalized from such psychoanalytic theories, though such ego psychology-based lines of development diverged substantially from the paths taken elsewhere within psychoanalysis.

The philosopher and psychiatrist Karl Jaspers made influential use of a "biographical method" and suggested ways to diagnose based on the form rather than content of beliefs or perceptions. In regard to classification in general he prophetically remarked that: "When we design a diagnostic schema, we can only do so if we forego something at the outset … and in the face of facts we have to draw the line where none exists... A classification therefore has only provisional value. It is a fiction which will discharge its function if it proves to be the most apt for the time".

Adolph Meyer advanced a mixed biosocial scheme that emphasized the reactions and adaptations of the whole organism to life experiences.

In 1945, William C. Menninger advanced a classification scheme for the US army, called Medical 203, synthesizing ideas of the time into five major groups. This system was adopted by the Veterans Administration in the United States and strongly influenced the DSM.

The term stress, having emerged from endocrinology work in the 1930s, was popularized with an increasingly broad biopsychosocial meaning, and was increasingly linked to mental disorders. The diagnosis of post-traumatic stress disorder was later created.

Mental disorders were first included in the sixth revision of the International Classification of Diseases (ICD-6) in 1949. Three years later, in 1952, the American Psychiatric Association created its own classification system, DSM-I.

The Feighner Criteria group described fourteen major psychiatric disorders for which careful research studies were available, including homosexuality. These developed as the Research Diagnostic Criteria, adopted and further developed by the DSM-III.

The DSM and ICD developed, partly in sync, in the context of mainstream psychiatric research and theory. Debates continued and developed about the definition of mental illness, the medical model, categorical vs dimensional approaches, and whether and how to include suffering and impairment criteria. There is some attempt to construct novel schemes, for example from an attachment perspective where patterns of symptoms are construed as evidence of specific patterns of disrupted attachment, coupled with specific types of subsequent trauma.

21st century

The ICD-11 and DSM-5 are being developed at the start of the 21st century. Any radical new developments in classification are said to be more likely to be introduced by the APA than by the WHO, mainly because the former only has to persuade its own board of trustees whereas the latter has to persuade the representatives of over 200 countries at a formal revision conference. In addition, while the DSM is a bestselling publication that makes huge profits for APA, the WHO incurs major expense in determining international consensus for revisions to the ICD. Although there is an ongoing attempt to reduce trivial or accidental differences between the DSM and ICD, it is thought that the APA and the WHO are likely to continue to produce new versions of their manuals and, in some respects, to compete with one another.

Criticism

There is some ongoing scientific doubt concerning the construct validity and reliability of psychiatric diagnostic categories and criteria even though they have been increasingly standardized to improve inter-rater agreement in controlled research. In the United States, there have been calls and endorsements for a congressional hearing to explore the nature and extent of harm potentially caused by this "minimally investigated enterprise".

Other specific criticisms of the current schemes include: attempts to demonstrate natural boundaries between related syndromes, or between a common syndrome and normality, have failed; inappropriateness of statistical (factor-analytic) arguments and lack of functionality considerations in the analysis of a structure of behavioral pathology; the disorders of current classification are probably surface phenomena that can have many different interacting causes, yet "the mere fact that a diagnostic concept is listed in an official nomenclature and provided with a precise operational definition tends to encourage us to assume that it is a "quasi-disease entity" that can be invoked to explain the patient's symptoms"; and that the diagnostic manuals have led to an unintended decline in careful evaluation of each individual person's experiences and social context.

Psychodynamic schemes have traditionally given the latter phenomenological aspect more consideration, but in psychoanalytic terms that have been long criticized on numerous grounds.

Some have argued that reliance on operational definition demands that intuitive concepts, such as depression, need to be operationally defined before they become amenable to scientific investigation. However, John Stuart Mill pointed out the dangers of believing that anything that could be given a name must refer to a thing and Stephen Jay Gould and others have criticized psychologists for doing just that. One critic states that "Instead of replacing 'metaphysical' terms such as 'desire' and 'purpose', they used it to legitimize them by giving them operational definitions. Thus in psychology, as in economics, the initial, quite radical operationalist ideas eventually came to serve as little more than a 'reassurance fetish' (Koch 1992, 275) for mainstream methodological practice." According to Tadafumi Kato, since the era of Kraepelin, psychiatrists have been trying to differentiate mental disorders by using clinical interviews. Kato argues there has been little progress over the last century and that only modest improvements are possible in this way; he suggests that only neurobiological studies using modern technology could form the basis for a new classification.

According to Heinz Katsching, expert committees have combined phenomenological criteria in variable ways into categories of mental disorders, repeatedly defined and redefined over the last half century. The diagnostic categories are termed "disorders" and yet, despite not being validated by biological criteria as most medical diseases are, are framed as medical diseases identified by medical diagnoses. He describes them as top-down classification systems similar to the botanic classifications of plants in the 17th and 18th centuries, when experts decided a priori which visible aspects of plants were relevant. Katsching notes that while psychopathological phenomena are certainly observed and experienced, the conceptual basis of psychiatric diagnostic categories is questioned from various ideological perspectives.

Psychiatrist Joel Paris argues that psychiatry is sometimes susceptible to diagnostic fads. Some have been based on theory (overdiagnosis of schizophrenia), some based on etiological (causation) concepts (overdiagnosis of post-traumatic stress disorder), and some based on the development of treatments. Paris points out that psychiatrists like to diagnose conditions they can treat, and gives examples of what he sees as prescribing patterns paralleling diagnostic trends, for example an increase in bipolar diagnosis once lithium came into use, and similar scenarios with the use of electroconvulsive therapy, neuroleptics, tricyclic antidepressants, and SSRIs. He notes that there was a time when every patient seemed to have "latent schizophrenia" and another time when everything in psychiatry seemed to be "masked depression", and he fears that the boundaries of the bipolar spectrum concept, including in application to children, are similarly expanding. Allen Frances has suggested fad diagnostic trends regarding autism and Attention deficit hyperactivity disorder.

Since the 1980s, psychologist Paula Caplan has had concerns about psychiatric diagnosis, and people being arbitrarily "slapped with a psychiatric label". Caplan says psychiatric diagnosis is unregulated, so doctors aren't required to spend much time understanding patients situations or to seek another doctor's opinion. The criteria for allocating psychiatric labels are contained in the Diagnostic and Statistical Manual of Mental Disorders, which can "lead a therapist to focus on narrow checklists of symptoms, with little consideration for what is causing the patient’s suffering". So, according to Caplan, getting a psychiatric diagnosis and label often hinders recovery.

The DSM and ICD approach remains under attack both because of the implied causality model and because some researchers believe it better to aim at underlying brain differences which can precede symptoms by many years.

Drugs in pregnancy

From Wikipedia, the free encyclopedia

Drugs and medications should be avoided while pregnant. Women should speak to their doctor or healthcare professional before starting or stopping any medications while pregnant. Tobacco, alcohol, marijuana, and illicit drug use while pregnant may be dangerous for the unborn baby and may lead to severe health problems and/or birth defects. Even small amounts of alcohol, tobacco, and marijuana have not been proven to be safe when taken while pregnant. In some cases, for example, if the mother has epilepsy or diabetes, the risk of stopping a medication may be worse than risks associated with taking the medication while pregnant. The mother's healthcare professional will help make these decisions about the safest way to protect the health of both the mother and unborn child. In addition to medications and substances, some dietary supplements are important for a healthy pregnancy, however, others may cause harm to the unborn child.

The Food and Drug Administration (FDA) in the United States reports that there are six million pregnancies with at least 50% of the women taking at least one medication. In addition a reported 5–10% of women of childbearing age use alcohol or addictive substances. Of those who bear children, recreational drug use can have serious consequences to the health of not only the mother, but also the fetus as many medications can cross the placenta and reach the fetus. Some of the consequences on the babies include physical abnormalities, higher risk of stillbirth, neonatal abstinence syndrome (NAS), sudden infant death syndrome (SIDS), and others.

Medications

Some medications can cause harm to the unborn baby, but in some instances the benefits may outweigh the risks to the baby or mother. A woman who has diabetes mellitus may need intensive therapy with insulin to prevent complications to the mother and baby.

Medications used to treat diabetes

Gestational diabetes is a form of diabetes that is first diagnosed during pregnancy and can accordingly cause high blood sugar that affects the woman and the baby. In 10 - 20% of women whose diet and exercise are not adequate enough to control blood sugar, insulin injections may be required to lower blood sugar levels. Medications that can be used in diabetes during pregnancy include insulin, glyburide and metformin.

Pain Medications

The most common over-the-counter pain-relieving medications include aspirin, acetaminophen (Tylenol), and non-steroidal anti-inflammatory drugs (NSAIDs), which include naproxen (Aleve), ibuprofen (Advil/Motrin), among others. The safety of these medications vary by class and by strength.

Pregnant women who use prescription medications containing opioids while pregnant may cause serious harm to the mother or unborn child. For some people, the risk of stopping a medication such as prescription opioids may be more serious than the risk of taking a medication.

Acetaminophen

Short-term use of acetaminophen as directed is one of the only medications recommended for treating pain and fever in women who are pregnant. There is no established association with teratogenicity or elevated occurrence of birth defects and the usage of acetaminophen at any point during a pregnancy. There is potential for fetal liver toxicity in cases of maternal overdose, where the mother consumes more than the recommended daily dose.

Non-steroidal anti-inflammatory medications (NSAIDs)

Ibuprofen and naproxen have not frequently been studied during pregnancy, but recent studies do not show increased risk of spontaneous abortion within the first six weeks of pregnancy. However, all NSAIDs showed association with structural cardiac defects with usage during the early weeks of pregnancy. When ibuprofen and naproxen are used within the third trimester, there is a significant increase in the risk of premature closure of the ductus arteriosus with primary pulmonary hypertension in the newborn. Between the lack of studies of the effect of ibuprofen and naproxen on pregnancy, it is recommended that pregnant women avoid these medications or use them sparingly per physician recommendations.

Aspirin

Usage of aspirin during pregnancy is not recommended. Aspirin use during pregnancy has not demonstrated an increased risk of spontaneous abortion within the early weeks of pregnancy. However, its usage during organogenesis and the third trimester can lead to elevated risk of intrauterine growth retardation and maternal hemorrhage.

Pain medications containing opioids

For more information, see the below section on Recreational drugs

Any medications containing opioids may be dangerous for the unborn baby and should not be taken while pregnant.

Anticonvulsant medications

Most women with epilepsy deliver healthy babies and have a healthy pregnancy, however, some women with epilepsy are at a higher risk for losing their baby (stillborn) and of the baby having birth defects such as neural tube defects. Women who have epilepsy require advice from their doctor to determine the safest way to protect both the mother and unborn child from health risks associated with seizures and the risk of birth defects associated with some of the commonly prescribed anticonvulsant medications. Valproic acid and its derivatives such as sodium valproate and divalproex sodium may cause congenital malformations (birth defects). An increased dose causes decreased intelligence quotient. Valproic acid use during pregnancy increases the risk of neural tube defects by approximately 20-fold. Evidence is conflicting for carbamazepine regarding any increased risk of congenital physical anomalies or neurodevelopmental disorders by intrauterine exposure. Similarly, children exposed to lamotrigine or phenytoin in the womb do not seem to differ in their skills compared to those who were exposed to carbamazepine.

Antacids

Heartburn is a common symptom of late term pregnancy during which up to 80% of pregnant women have experienced it by the end of their third trimester. Heartburn often indicates the development of gastro-esophageal reflux disease (GERD), where the lower esophageal sphincter relaxes due to elevated progesterone levels causing increased frequency and severity of gastric reflux or heartburn. If heartburn appears after 20 weeks of gestational age or is severe and persistent, this can indicate other conditions including HELLP syndrome and preeclampsia.

Common antacids include aluminum hydroxide/magnesium hydroxide (Maalox) and calcium carbonate (Tums). Histamine H2 blockers and proton pump inhibitors, such as famotidine (Pepcid) and omeprazole (Prilosec), respectively, can also be used to help relieve heartburn, with no known teratogenic effects or congenital malformations. Aluminum hydroxide/magnesium hydroxide and calcium carbonate, when consumed, do not cross the placenta and are regarded as safe pharmacological options to treat heartburn, since there are no significant association with maldevelopment or injury to fetus.

Ginger and acupressure are common non-pharmacological options used to treat nausea and vomiting as alternatives to antacids, histamine H2 blockers, and proton pump inhibitors. Lifestyle modifications are often recommended as well. Recommended modifications can include avoiding fatty food, reducing size and frequency of meals, and reducing caffeine intake.

Antiacne

Acne vulgaris (acne) can occur in pregnancy possibly due to the hormonal changes influencing sebum production. There are limited antiacne medications that are safe in pregnancy. External applications of azelaic acid, glycolic acid, or benzoyl peroxide (alone or combined with clindamycin or erythromycin) are the safest options to treat mild to moderate acne. Erythromycin is the antibiotic of choice for severe acne, barring the use of its estolate salt which risks maternal hepatotoxicity. Topical nicotinamide and topical zinc are safe, however, there are no FDA pregnancy category ratings. Topical salicylic acid and topical dapsone are classified as FDA pregnancy category C. Acne medications to avoid during pregnancy include oral isotretinoin and topical tazarotene as there have been reports of birth defects. As safety data is lacking, the use of topical retinoids, such as adapalene and tretinoin, is not recommended. Antiandrogenic drugs, including spironolactone and cyproterone acetate, should be avoided. If planning to conceive while using contraindicated medications, a washout and waiting period before conception is advised. A herbal product, vitex agnus-castus should not be used during gestation due to undesirable hormonal effects.

Safety data supports the use of blue and red light therapy as non-drug treatments to consider. Personal hygiene and a healthy lifestyle also help, however dietary restriction and abrasive agents found in facial cleaning products are not beneficial. As there are limited options to safely treat acne in pregnancy, shared decision-making between the health care provider and client is recommended.

Anticoagulants

Anticoagulants are medications that prevent the blood from forming clots and are also known as blood thinners. These medications are commonly used for both prevention and treatment in people who are at risk for or have experienced a heart attack, stroke, or venous thromboembolism. Pregnancy increases the risk of clot formation in women due to elevated levels of certain clotting factors and compounds in the body, and the risk increases even more immediately after birth and remains elevated up to 3 months after delivery. Anticoagulants must be prescribed with caution as these medications can have negative health consequences for the developing baby and need to consider dosing and medication management options.

Warfarin

Warfarin (brand name Coumadin) is a commonly prescribed blood thinner both in the inpatient and outpatient hospital settings. In pregnant women, warfarin is contraindicated and should be avoided as it crosses the placental barrier. Additionally, warfarin is listed as Pregnancy Category D, which means it has a risk of harming the fetus. However, it has been shown that daily warfarin doses up to 5 mg may be beneficial for pregnant women who are at higher risk of thromboembolism.

Low Molecular Weight Heparin (LMWH)

A common low molecular weight heparin drug is called enoxaparin (brand name Lovenox). Enoxaparin is listed as Pregnancy Category B, meaning animal studies have failed to show harmful effects to the fetus and therefore are safe to use in pregnant women. However, pregnant women taking LMWH may not experience the full anticoagulant effect due to the nature of the medication compared to other anticoagulants (i.e. warfarin) and may be less favorable for users as it is an injectable medication.

Unfractionated Heparin (UFH)

Unfractionated heparin is another type of anticoagulant that has been widely used. UFH is classified as Pregnancy Category C, which means animal studies have shown potential for adverse effects to the fetus; however, there needs to be more studies done to confirm the presence of a risk to the fetus. UFH can be used in pregnant women as long as the benefits outweigh the risk.

Direct Oral Anticoagulants (DOACs)

Direct oral anticoagulants are newer types of anticoagulants that are available as oral medications and are widely used in non-pregnant populations. As many studies looking at DOACs exclude pregnant women, there is not enough evidence to demonstrate the safety and efficacy of DOACs in pregnant women. Currently, rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa) are DOACs listed under Pregnancy Category C, and apixaban (Eliquis) is listed under Pregnancy Category B.

Antidiarrheal

Diarrhea is not a common symptom of pregnancy; however, it can occur as a result of reduced gastric acidity and slowed intestinal motility. Bismuth subsalicylate (Pepto-Bismol), loperamide (Imodium), and atropine/diphenoxylate (Lomotil) are antidiarrheal agents that can be used to treat diarrhea. However, not all of them are safe to use during pregnancy. One of the components of bismuth subsalicylate is salicylate, which is a component that crosses the placenta. Due to this, there is an increased risk for intrauterine growth retardation, fetal hemorrhage, and maternal hemorrhage within organogenesis and in the second/third trimester. Loperamide has limited data on the impact it has on pregnancy, but there is an association with cardiovascular malformation in the first trimester. Atropine/diphenoxylate currently has insufficient evidence of teratogenicity in humans, but trials with animals showed evidence of teratogenic effects.

Antihistamines

Antihistamines may be prescribed in early pregnancy for the treatment of nausea and vomiting along with symptoms of asthma and allergies. First generation antihistamines include diphenhydramine (Benadryl), chlorpheniramine (Diabetic Tussin), hydroxizine (Atarax), and doxepin (Sinequan). Second generation antihistamines include loratadine (Claritin), cetrizine (Zyrtec), and fexofenadine (Allegra). First generation antihistamines have the ability to cross the blood-brain barrier which can result in sedative and anticholinergic effects while effectively treating allergic reactions and nausea and vomiting related to pregnancy. On the other hand, second generation antihistamines do not cross the blood-brain barrier, thus eliminating sedating effects. Currently, there is a lack of association between prenatal antihistamine exposure and birth defects.

Antihistamines during pregnancy have not been linked to birth defects; however, further research is necessary for some antihistamine medications to determine safety during pregnancy. It is suggested that women speak to their healthcare professionals before taking any over-the-counter or prescription medication while pregnant to ensure that there are no adverse health outcomes.

Anti-hypertensives

Hypertensive issues are the most common cardiovascular disorders during pregnancy, occurring within 5 to 10% of all pregnant females. Anti-hypertensives are blood pressure medications used to treat high blood pressure in pregnant women. This class of medication is commonly used to treat problems such as heart failure, heart attack, and kidney failure. Caution must be exercised with the use of various hypertensive agents for the treatment of blood pressure. While the drug classes of Angiotensin Converting Enzyme inhibitors (ACEi), Angiotensin Receptor Blockers (ARB), and angiotensin receptor neprilysin inhibitors (ARNI) have been shown to be potent anti-hypertensive agents, their use is advised against during pregnancy. ACEi and ARB have known fetotoxicities when used during the second or third trimester or both. Signs and symptoms of ACEi and ARB use during pregnancy include kidney damage or failure, oligohydramnios, anuria, joint contractures, and hypoplasia of the skull. Common, alternative agents for high blood pressure in pregnant women include anti-adrenergic and beta-blocking medications, such as methyldopa or metoprolol, respectively.

Decongestants

Decongestants are often used in conjunction with cold medications or to combat pregnancy rhinitis in pregnant women. Common decongestants include pseudoephedrine and phenylephrine. Pseudoephedrine is an alpha-adrenergic receptor agonist that enacts a vasoconstrictive effect to reduce airflow resistance in the nasal cavity and allow easier breathing by relieving a stuffy or congested nose. When taken in early trimesters, there has been limited evidence to associate pseudoephedrine with birth defects. However, studies often found it difficult to isolate pseudoephedrine's involvement, due to the variety of combination products that contain pseudoephedrine in conjunction with other medications. Since pseudoephedrine activates alpha adrenergic receptors, it has the ability to elevate blood pressure and cause vasoconstriction within the uterine arteries. This can negatively affect blood flow to the fetus. Due to the lack of studies, decongestants in combination drugs or isolated forms are suggested to be used sparingly during pregnancy. Saline nasal sprays, among other non-pharmacological treatments, are considered to be safe alternatives for decongestants.

Dietary supplements

Dietary supplements such as folic acid and iron are important for a healthy pregnancy. Some dietary supplements can cause side effects and harm to the mother or unborn child. Pregnant women should discuss all dietary supplements with their health care professional to determine the appropriate dosage and which supplements are safe during pregnancy.

Caution should be taken before consuming dietary supplements while pregnant as dietary supplements are considered "foods" rather than medications and are not regulated for safety and efficacy by the FDA.

Illicit and recreational drugs

Alcohol

Alcohol should not be consumed while pregnant. Even a small amount of alcohol is not known to be safe for the unborn baby. Alcohol passes easily from the mother's bloodstream through the placenta and into the bloodstream of the fetus. Since the fetus is smaller and does not have a fully developed liver, the concentration of alcohol in its bloodstream lasts longer, increasing the chances of detrimental side effects. The severity of effects alcohol may have on a developing fetus depends upon the amount and frequency of alcohol consumed as well as the stage of pregnancy. Rates of alcohol consumption can generally be categorized in one of three ways: heavy drinking (more than 48-60 grams of ethanol/day), moderately high drinking (24-48 grams of ethanol/day), and binge drinking (4-5 drinks/90 grams of ethanol at a time). Heavy drinking and binge drinking are closely associated with a higher risk of fetal alcohol spectrum disorders (FASDs). The most severe form of FASD is fetal alcohol syndrome (FAS). This used to be the only diagnosis for fetal disorders due to alcohol consumption, but the term was broadened to a "spectrum" due to the variety of abnormalities observed in newborns. This was most likely because of the different amounts of alcohol ingested during pregnancy indicating that there is not a clear, specific dose that determines if a fetus will be affected by alcohol or not. FAS is characterized by slower physical growth, distinct facial abnormalities including smooth philtrum, thin vermilion, and short palpebral fissures, neurological deficits, or smaller head circumference. Other problems associated with FASD include delayed or uncoordinated motor skills, hearing or vision problems, learning disabilities, behavior problems, and inappropriate social skills compared to same-age peers. Those affected are more likely to have trouble in school, legal problems, participate in high-risk behaviors, and develop substance use disorders themselves.

Caffeine

Caffeine is a widespread drug consumed by adults due to its behavioral and stimulating effects. According to the American College of Obstetricians and Gynecologists, an acceptable intake of caffeine for pregnant women is less than or equal to 200 mg per day. Consumption of caffeine is not associated with adverse reproductive and developmental effects. The half-life of caffeine is longer in pregnancy by 8 to 16 more hours, which means that caffeine stays in the person longer, increases fetal exposure to caffeine, and is eliminated slower in the body. Other comprehensive reviews reported that caffeine intake of more than 300 mg per day have been associated with spontaneous abortions and low birth weight, but further research is needed to establish this causal relationship.

Cannabis

Cannabis use during pregnancy should be avoided. There is no known safe dose of cannabis while pregnant and use of cannabis may lead to birth defects, pre-term birth, or low birth weight. Tetrahydrocannabinol (THC), an active ingredient in cannabis, can both cross the placenta and accumulates in high concentrations in breast milk. Cannabis consumption in pregnancy might be associated with restrictions in growth of the fetus, miscarriage, and cognitive deficits. Infants exposed to prenatal cannabis may show signs of increased tremors and altered sleep patterns. Cannabis is the most frequently used, illicit drug amongst pregnant women. There are significant limitations to the current research available. One limitation is because most studies done are dated in the 1980s. Additionally, many studies done on cannabis that evaluate its safety often fail to account for confounding factors, a variable that could also be having an effect on an outcome that is not the test variable. For example, tobacco use and sociodemographic differences are often not adjusted for accordingly in many studies.

Cocaine

Use of cocaine in pregnant women is dangerous and can lead to cardiovascular complications like hypertension, myocardial infarction and ischemia, kidney failure, liver rupture, cerebral ischemia, cerebral infarction, and maternal death. Cardiac muscles become more sensitive to cocaine in pregnancy, in the presence of increasing progesterone concentrations. Cocaine use leads to increased risk for perinatal outcomes: preterm delivery, low birth weight (less than 2500 grams) or reduced birth rate, small size and earlier gestational age at delivery.

Prenatal cocaine exposure (PCE) is associated with premature birth, birth defects, attention deficit hyperactivity disorder (ADHD), and other conditions.

Methamphetamine

Use of methamphetamine is dangerous for pregnant women and to the unborn baby. Methamphetamines are a class of drugs that provide stimulant-like effects, including euphoria and alertness. The drug crosses the placenta and affects the fetus during the gestational stage of pregnancy. Methamphetamine use in pregnancy may lead to babies born with an earlier gestational age at delivery (pre-term), lower birth weight, and smaller head circumference. Methamphetamine use during pregnancy also negatively impacts brain development and behavioral functioning and increases the risk of the baby having ADHD and lower mental processing speed.

Opioids

Opioids such as heroin, fentanyl, oxycodone and methadone should not be taken while pregnant. Opioid use during pregnancy may cause adverse outcomes for the women and unborn child. Women who use opioids during pregnancy in a non-medical fashion are at a higher risk for premature birth, lower birth weight, still birth, specific birth defects, and withdrawal (neonatal abstinence syndrome).

Opioids can cross the placenta and the blood brain barrier to the fetus. Opioid use is the main cause of neonatal abstinence syndrome, which is where the baby experiences withdrawals from the opioid they were exposed to during the pregnancy. Typical symptoms may include tremors, convulsions, twitching, excessive crying, poor feeding or sucking, slow weight gain, breathing problems, fever, diarrhea, and vomiting. There is no consensus on the effects on cognitive abilities. Further research is required to determine the long-term effects of in utero exposure to opioid medications on children.

Tobacco

Smoking during pregnancy is dangerous to the unborn baby and may cause pre-term birth, birth defects such as cleft lip or cleft palate, or miscarriage. Tobacco is the most commonly used substance among pregnant women, at 25%. Nicotine crosses the placenta and accumulates within fetal tissues. Children born to women who smoked heavily were more susceptible to behavioral problems such as ADHD, poor impulse control, and aggressive behaviors. Tobacco contains carbon monoxide, which has the potential to prevent the fetus from receiving sufficient oxygen. Other health concerns tobacco poses are premature birth, low birth weight, and an increased risk of sudden infant death syndrome (SIDS) of up to three times compared to infants not exposed to tobacco. Smoking and pregnancy, combined, cause twice the risk of premature rupture of membranes, placental abruption and placenta previa. In addition to the fetus, women in general who smoke heavily are less likely to become pregnant.

Pregnancy categories

Until 2014, the U.S. Code of Federal Regulations required that certain drugs and biological products be labelled specifically with respect to their effects on pregnant populations, including a definition of a "pregnancy category". These rules were enforced by the FDA, and medications that have been studied for their effects in pregnancy fell under the following Pregnancy Categories: A, B, C, D, or X depending on how they have been studied and what kind of results were found from the studies. In 2014, however, the FDA has developed a "Pregnancy and Lactation Labeling Rule (PLLR)" which requires product labels to include specific information related to the safety and effectiveness of medications to pregnant and lactating women. This ruling has removed the requirement of stating pregnancy categories in prescription drug labels.

Australia's categorization system takes into account birth defects, the effects around birth or when the mother gives birth, and problems that will arise later in the child's life due to the drug taken. The system places them into a category based on the severity of the consequences that the drug can have on the infant when it crosses the placenta.

NASA lunar outpost concepts

From Wikipedia, the free encyclopedia
 
Concept art from NASA showing astronauts entering a lunar outpost. (2006)

NASA has made many concepts of moonbases for achieving a permanent presence of humans on the Moon. The American government agency requested an increase in the 2020 budget of $1.6 billion, in order to make another crewed mission to the Moon by 2025 (originally 2024), followed by a sustained presence on the Moon by 2028.

History

The concept of establishing a long-term human presence on the Moon can be traced back to the late 1950s. The Lunex Project, conceptualized in 1958, was a US Air Force plan to construct an underground Air Force Base on the Moon. On 8 June 1959, the US Army's Ballistic Missile Agency (ABMA) organized a task force called Project Horizon to assess the feasibility of constructing a military base on the Moon.

Project Horizon proposed using a series of Saturn launches to pre-construct an outpost while in Earth orbit, with the intention of subsequently delivering and landing the completed assembly on the Moon. Additional Saturn launches each month would then ship supplies to the inhabitants.

An early lunar outpost design based on a module design. A connecting tunnel to the left permits the outpost module to connect to landers, rovers or other modules. Much of the equipment is built into standardized racks. Much of the hardware in the early outpost will be dedicated to crew health. Concept: NASA (1990)
 
A lunar base for six to twelve people, built into an inflatable spherical habitat. Proportions of the interior volume devoted to different systems equipment are relatively accurate. The heaviest equipment such as for environmental control, and areas in which the crew spends the most time, such as their personal sleep quarters are lowest in the habitat. Work areas for lunar sample analysis, hydroponics, and even for small animals are located in the middle areas. The top deck in this view is a running track on which the sloped surface permits the crew member to use centripetal force rather than gravity to permit running in 1/6 G. Concept: NASA (1989)
 
Heavy, pressurized lunar rover for long-duration treks across the Moon's surface. The rover contains all facilities and supplies to house approx 4 crew for up to 2 weeks. A crew airlock permits the crew to exit and enter the rover and may double as a docking port to the lunar base. A smaller sample airlock permits the crew, using remote manipulators mounted on the rover front to select, pick up, and retrieve samples without exiting the rover. The wheel design is based on one of the more favorable flex wheels developed during Apollo. The cupola on top is important for viewing the terrain at a much greater distance and along 360 degrees of the horizon and is based on the ISS cupola design. Concept: NASA (1990)

A lunar outpost was an element of the George W. Bush era Vision for Space Exploration, which has been replaced with President Barack Obama's space policy. The outpost would have been an inhabited facility on the surface of the Moon. At the time it was proposed, NASA was to construct the outpost over the five years between 2019 and 2024. The United States Congress directed that the U.S. portion, "shall be designated the Neil A. Armstrong Lunar Outpost".

On 4 December 2006, NASA announced the conclusion of its Global Exploration Strategy and Lunar Architecture Study. The Lunar Architecture Study's purpose was to "define a series of lunar missions constituting NASA's Lunar campaign to fulfill the Lunar Exploration elements" of the Vision for Space Exploration. What resulted was a basic plan for a lunar outpost near one of the poles of the Moon, which would permanently house astronauts in six-month shifts. These studies were made before the discovery of water ice (5.6 ± 2.9% by mass) in a polar crater, which may substantially affect plans.

1984 Johnson Space Center lunar outpost concept

In 1984, with the Space Shuttle in service, a team based at the Johnson Space Center made a feasibility study for NASA's return to the Moon. It anticipated later studies in using NASA's planned infrastructure – the Shuttle, a Shuttle-derived heavy lift vehicle, a space station, and an orbital transfer vehicle – to build a permanent 18-crew Moon base sometime between 2005 and 2015.

Design details

The Space Shuttle was to have transported the empty 21,000-kilogram lunar lander and payload to the space station, where they would rendezvous with the 100 ton propellant module.

The first objective was the creation of small semipermanently manned "camp" on the lunar surface in 2005-2006.

NASA was to have launched a lunar orbiting space station in 2008-2009 to support the creation of a permanently manned moonbase by 2009-2010.

This operational surface base would have contained an expanded mining facility, lunar materials processing pilot plants and a lunar agriculture research laboratory; pilot oxygen production and experimental mining facilities would have been landed previously.

The lunar surface facility would have grown to an 18-crew "advanced base" in 2013-14, consisting of five habitation modules, a geochemical laboratory, chemical/biological lab, geochemical/petrology lab, a particle accelerator, a radio telescope, lunar oxygen, ceramics and metallurgy plants, two shops, three power units (90% lunar-materials derived), one earthmover/crane and three trailers/mobility units. The ultimate goal would be a self-sustaining moonbase by 2017-18.

The following were the names of vehicles or mission steps associated with the JSC Moon Base:

  • Mapper and L-2 Relay Satellite. Development: 1992-1996. First launch: 1996.
  • Surface Explorer Rover. Development: 1995-1999. First launch: 1999.
  • Expendable Lander. Development: 1995-1999. First launch: 1999.
  • Network and Regolith Science. Development: 2002-2004.
  • Manned Capsule / OTV. Development: 1999-2003. First launch: 2003.
  • Expendable Ascent Stage. Development: 1999-2003. First launch: 2003.
  • Lunar Orbital Facilities. Development: 2004-2008. First launch: 2008-2009.
  • Camp, temporary manned. Development: 2000-2004. First launch: 2005-2006.
  • Base, permanent manned. Development: 2004-2009. First launch: 2009-2010.
  • Advanced Base. Development: 2008-2013. First launch: 2013-2014.
  • Self-Sustaining Base. Development: 2012-2016. First launch: 2017-2018.
The LREC lunar outpost

1994 International Lunar Resources Exploration Concept

The International Lunar Resources Exploration Concept (ILREC) was a proposed mission architecture under President George H. W. Bush's Space Exploration Initiative (SEI) by Kent Joosten, an engineer at Johnson Space Center. The plan would have used the help of international partners, mainly Soviet Union, to assemble a lunar base and sustainable lunar transportation service. The program was not able to get off the ground as it was proposed at the end of SEI's very short lifespan with the only surviving project being Space Station Freedom (now the International Space Station)

2005 Exploration Systems Architecture Study

The Exploration Systems Architecture Study (ESAS) is the official title of a large-scale, system-level study released by NASA in November 2005 in response to American president George W. Bush's announcement on 14 January 2004 of his goal of returning astronauts to the Moon and eventually Mars— known as the Vision for Space Exploration (and unofficially as "Moon, Mars and Beyond" in some aerospace circles, though the specifics of a human "beyond" program remain vague).

2006 Reference Architecture

A reference architecture was established for this outpost, based on a location on the rim of the Shackleton crater, located in the immense South Pole-Aitken basin, near the Moon's south pole. At a presentation, on 4 December 2006, Doug Cooke, Deputy Associate Administrator, NASA Exploration Systems Mission Directorate, described an area "that is ... sunlit ... 75 to 80 percent of the time, and it is adjacent to a permanently dark region in which there is potentially volatiles that we can extract and use. ... This sunlit area is about the size of the Washington Mall." (approximately 1.25 km²). The Indian Chandrayaan-1 orbiter (2008–2009) helped in the determination of the precise location of the outpost.

Other locations considered for possible lunar outposts included the rim of Peary crater near the lunar north pole and the Malapert Mountain region on the rim of Malapert crater.

The outpost design included:

The outpost would have been supplied by a mixed crew and cargo Altair lander, capable of bringing four astronauts and a payload of six tons to the Moon's surface.

As planned, an incremental buildup would begin with four-person crews making several seven-day visits to the moon until their power supplies, rovers and living quarters were operational. The first mission would begin by 2020. This would be followed by 180-day missions to prepare for journeys to Mars.

2008 Concepts Study

On 6 June 2008, NASA announced a set of six research opportunities and requested proposals for research funding in response to the announcement. The overall budget for research conducted as part of this "Lunar Surface Systems Concepts Study" was believed to be $2 million. Proposals were selected and contracts awarded in August 2008 by the NASA Constellation Lunar Surface Systems Project Office (LSSPO).

2010/2011 surface system concept review

The LSSPO was established at the Johnson Space Center in August 2007. The LSSPO was studying lunar surface systems such as "habitation systems", ISRU, rovers, power production and storage, systems to meet science and exploration objectives and safety systems. The LSSPO was expected to conduct a surface system concept review in the 2010 or 2011 timeframe.

2017/Present: Artemis program

The Artemis program is a planned crewed spaceflight program carried out predominately by NASA, U.S. commercial spaceflight companies, and international partners such as the European Space Agency (ESA), JAXA, and the Canadian Space Agency (CSA) with the goal of landing "the first woman and the next man" on the Moon, specifically at the lunar south pole region by 2024. NASA sees Artemis as the next step towards the long-term goal of establishing a sustainable presence on the Moon, laying the foundation for private companies to build a lunar economy, and eventually sending humans to Mars. One primary target is Shackleton crater. In 2028 NASA plans on launching the Lunar Surface Asset, a small habitat to the surface of the Moon on either an SLS Block 1B or through an Artemis Support Mission on a commercial launcher. This would be the first crewed lunar base.

Justification

In the words of former NASA Administrator, Michael D. Griffin,

The goal isn't just scientific exploration. ... It's also about extending the range of human habitat out from Earth into the solar system as we go forward in time. ... In the long run a single-planet species will not survive. ... If we humans want to survive for hundreds of thousands or millions of years, we must ultimately populate other planets. Now, today the technology is such that this is barely conceivable. We're in the infancy of it. ... I'm talking about that one day, I don't know when that day is, but there will be more human beings who live off the Earth than on it. We may well have people living on the moon. We may have people living on the moons of Jupiter and other planets. We may have people making habitats on asteroids ... I know that humans will colonize the solar system and one day go beyond.

Lunar Gateway

A station in lunar orbit can serve as a communications hub, temporary habitation module, and holding area for rovers and other robots intended for an outpost on lunar ground. NASA leads a proposal for such a station, titled Lunar Gateway. The omnibus spending bill passed by Congress in March 2018 provided NASA with $504 million for preliminary studies during the 2019 fiscal year. The final funding amount enacted by Congress was slightly lower at $450 million.

Criticism

Criticisms come from groups that want the human exploration money diverted to Mars, from those who prefer uncrewed exploration, and from those who simply want the money spent elsewhere. The criticisms listed here mostly predate the discovery of significant amounts of polar water ice. Jeff Foust, writing for The Space Review, called the six themes that NASA released too "broad" and the explanations supporting them "shallow." He also argues that a Moonbase is a poor use of resources, since "science can be done for far less money by robotic missions—which also don't put human lives at risk." The Los Angeles Times seconded that in an editorial, saying "Manned moon flight may appeal to baby boomers, but it makes little scientific sense for most space missions these days. Robots can now perform or be developed to perform, most of the tasks people would do at a moon station."

Columnist Gregg Easterbrook, who has reported on the space program for decades, has criticized the plans as a poor use of resources. He writes that

Although, of course, the base could yield a great discovery, its scientific value is likely to be small while its price is extremely high. Worse, moon-base nonsense may for decades divert NASA resources from the agency's legitimate missions, draining funding from real needs in order to construct human history's silliest white elephant.

According to Easterbrook, the billions of dollars that a lunar colony might cost should instead be devoted to exploring the Solar System with space probes; space observatories; and protecting the Earth from near-Earth asteroids.

Buzz Aldrin, the second of twelve men to have walked on the Moon, disagrees with NASA's current goals and priorities, including their plans for a lunar outpost. While not necessarily opposed to sending people back to the Moon, Aldrin argues that NASA should concentrate on a human mission to Mars and leave further lunar exploration and the establishment of a base there to a consortium of other countries under U.S. leadership. In a July 2009 editorial in the Washington Post, he said that NASA's Vision for Space Exploration "is not visionary; nor will it ultimately be successful in restoring American space leadership. Like its Apollo predecessor, this plan will prove to be a dead-end littered with broken spacecraft, broken dreams, and broken policies." He continued by saying that:

the lunar surface ... is a poor location for homesteading. The moon is a lifeless, barren world, its stark desolation matched by its hostility to all living things. And replaying the glory days of Apollo will not advance the cause of American space leadership or inspire the support and enthusiasm of the public and the next generation of space explorers.

Distance education

From Wikipedia, the free encyclopedia https://en.wikipedia.org/wiki/Distance_...